

SUPPLEMENTARY TABLE 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17 years,* by health insurance status† — National Immunization Survey–Teen (NIS-Teen), United States, 2017.

Vaccines	Health Insurance Status						
	Private Insurance Only (n = 12,027)	Any Medicaid (n = 6,504)	Other Insurance (n = 1,600)	Uninsured (n = 818)	Difference between Any Medicaid and Private Insurance (n = 18,531)	Difference between Other Insurance and Private Insurance (n = 13,627)	Difference between Uninsured and Private Insurance (n = 12,845)
	% (95% CI) [§]	% (95% CI) [§]	% (95% CI) [§]	% (95% CI) [§]	% (95% CI) [§]	% (95% CI) [§]	% (95% CI) [§]
Tdap[¶] ≥1 dose	89.5 (88.4 to 90.6)	87.8 (86.0 to 89.3)	89.3 (86.5 to 91.6)	86.6 (82.5 to 89.8)	-1.7 (-3.8 to 0.2)	-0.2 (-3.1 to 2.5)	-2.9 (-6.8 to 0.9)
MenACWY**							
≥1 dose	85.7 (84.4 to 86.9)	85.1 (83.3 to 86.8)	83.9 (80.4 to 86.9)	80.7 (76.5 to 84.4) ^{††}	-0.6 (-2.7 to 1.6)	-1.8 (-5.2 to 1.7)	-5.0 (-9.1 to -0.8) ^{††}
≥2 doses ^{§§}	44.1 (40.6 to 47.8)	49.4 (43.7 to 55.0)	38.5 (30.2 to 47.4)	21.5 (14.1 to 31.4) ^{††}	5.3 (-1.5 to 12.0)	-5.6 (-15.1 to 3.7)	-22.6 (-32.1 to -13.3) ^{††}
HPV^{¶¶} vaccination coverage							
All adolescents							
Receipt of ≥1 dose	62.5 (60.9 to 64.1)	71.3 (69.3 to 73.3) ^{††}	61.9 (57.7 to 65.9)	57.5 (51.8 to 62.9)	8.8 (6.3 to 11.4) ^{††}	-0.6 (-5.0 to 3.9)	-5.0 (-10.8 to 0.8)
HPV UTD ^{***}	46.7 (45.1 to 48.4)	53.3 (51.0 to 55.6) ^{††}	46.1 (41.9 to 50.4)	34.0 (29.0 to 39.5) ^{††}	6.6 (3.7 to 9.4) ^{††}	-0.6 (-5.2 to 3.9)	-12.7 (-18.3 to -7.2) ^{††}
MMR ≥2 doses	92.8 (91.8 to 93.6)	91.7 (90.1 to 93.0)	91.7 (88.8 to 93.9)	88.1 (84.3 to 91.1) ^{††}	-1.1 (-2.8 to 0.6)	-1.1 (-3.7 to 1.7)	-4.7 (-8.1 to -1.2) ^{††}
Hepatitis B ≥3 doses	92.1 (91.1 to 93.1)	92.0 (90.5 to 93.2)	92.4 (89.4 to 94.6)	88.1 (84.6 to 90.9) ^{††}	-0.1 (-1.8 to 1.5)	0.3 (-2.5 to 3.1)	-4.0 (-7.3 to -0.7) ^{††}
Varicella							
History of varicella ^{†††}	12.1 (11.0 to 13.4)	13.6 (12.1 to 15.3)	13.6 (11.0 to 16.8)	22.4 (18.3 to 27.2) ^{††}	1.5 (-0.5 to 3.5)	1.5 (-1.6 to 4.7)	10.3 (5.7 to 14.9) ^{††}
Among adolescents with no history of varicella disease							
≥1 vaccine dose	95.5 (94.6 to 96.4)	95.5 (94.0 to 96.6)	96.1 (94.6 to 97.2)	93.6 (90.0 to 96.0)	0.0 (-1.6 to 1.5)	0.6 (-1.0 to 2.1)	-1.9 (-4.9 to 1.1)
≥2 vaccine dose	88.6 (87.3 to 89.8)	89.3 (87.5 to 90.9)	86.0 (82.2 to 89.1)	85.8 (81.0 to 89.5)	0.7 (-1.4 to 2.8)	-2.6 (-6.3 to 1.1)	-2.8 (-7.2 to 1.6)
History of varicella or receipt of ≥2 varicella vaccine doses	90.0 (88.9 to 91.0)	90.8 (89.2 to 92.2)	87.9 (84.5 to 90.7)	89.0 (85.2 to 91.9)	0.8 (-1.0 to 2.6)	-2.1 (-5.3 to 1.2)	-1.0 (-4.5 to 2.5)

Abbreviations: CI = confidence interval; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; HPV = human papillomavirus; MMR = measles, mumps, and rubella vaccine; UTD = up to date; NA = not available (estimate not reported because unweighted sample size for the denominator was <30 or (95%CI half width / estimate) > 0.6).

* Adolescents (N = 20, 949) in the 2017 NIS-Teen were born January 1999 through February 2005.

† Adolescents' health insurance status was reported by parent or guardian. "Other insurance" includes the Children's Health Insurance Program (CHIP), military insurance, Indian Health Service, and any other type of health insurance not mentioned elsewhere.

§ Estimates with 95% confidence intervals >20 might be unreliable.

¶ Includes percentages receiving Tdap vaccine at age ≥10 years.

** Includes percentages receiving MenACWY or meningococcal vaccine of unknown type.

†† Statistically significant difference (p<0.05) in estimated vaccination coverage by health insurance status; referent group was adolescents with private insurance only.

§§ ≥2 doses of MenACWY or meningococcal vaccine of unknown type. Calculated only among adolescents aged 17 years at interview. Does not include adolescents who received one dose of MenACWY vaccine at age ≥16 years.

¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.

*** HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least five months minus four days elapsed between the first and second dose. This update to the HPV recommendation occurred in December of 2016.

††† By parent/guardian report or provider records.